Zhang J-J, Guo S-H, Jia B-Q
General Surgery Department II, Chinese PLA General Hospital, Beijing, China.
Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5143-5147.
The downregulation of Long non-coding RNA MEG3 (MEG3) has been observed in breast cancer (BC). However, there is no previous study of the relationship between MEG3 and patient prognosis in BC. Accordingly, this study investigated the prognostic values of MEG3 in BC patients.
we performed RT-qPCR to detect the expression of MEG3 in 207 paired BC tissues and adjacent noncancerous tissues. The association of MEG3 expression with clinicopathological factors or prognosis was statistically analyzed.
Our findings revealed that the MEG3 expression was significantly decreased in clinical BC tissues compared to adjacent normal tissues (p < 0.01). MEG3 level was significantly associated with differentiation grade (p = 0.004), TNM stage (p = 0.011) and lymph nodes metastasis (p = 0.000). Using Kaplan-Meier analysis, we found that patients with low MEG3 expression had significantly poor overall survival (OS) rate (p < 0.001) and progression-free survival (PFS) rate (p < 0.001). Moreover, multivariate Cox analysis revealed MEG3 expression was an independent poor prognostic factor for both 5-year OS (p = 0.003) and 5-year PFS (p = 0.002) in BC patients.
Our results indicated that MEG3 expression was an independent prognostic factor for patients with BC, which may serve as a novel biomarker in BC patients.
在乳腺癌（BC）中已观察到长链非编码RNA MEG3（MEG3）表达下调。然而，此前尚无关于MEG3与BC患者预后关系的研究。因此，本研究调查了MEG3在BC患者中的预后价值。
我们进行逆转录定量聚合酶链反应（RT-qPCR）以检测207对BC组织及相邻癌旁组织中MEG3的表达。对MEG3表达与临床病理因素或预后的相关性进行统计学分析。
我们的研究结果显示，与相邻正常组织相比，临床BC组织中MEG3表达显著降低（p < 0.01）。MEG3水平与分化程度（p = 0.004）、TNM分期（p = 0.011）及淋巴结转移（p = 0.000）显著相关。通过Kaplan-Meier分析，我们发现MEG3低表达患者的总生存率（OS）（p < 0.001）和无进展生存率（PFS）（p < 0.001）显著较差。此外，多因素Cox分析显示，MEG3表达是BC患者5年OS（p = 0.003）和5年PFS（p = 0.002）的独立不良预后因素。
我们的结果表明，MEG3表达是BC患者的独立预后因素，可能作为BC患者的一种新型生物标志物。
